Sign in or create an account to add this stock to your watchlist.
About Eiger Biopharmaceuticals (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-279-9845
Debt
Debt-to-Equity Ratio0.81
Current Ratio4.51
Quick Ratio4.51
Price-To-Earnings
Trailing P/E Ratio-2.60
Forward P/E Ratio-3.52
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.40 per share
Price / Book9.12
Profitability
EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-227.27%
Return on Assets-105.48%
Miscellaneous
Employees16
Outstanding Shares10,540,000
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) issued its earnings results on Friday, May, 11th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.96) by $0.12. View Eiger Biopharmaceuticals' Earnings History.
What price target have analysts set for EIGR?
7 analysts have issued twelve-month target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $39.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $31.4286 in the next twelve months. View Analyst Ratings for Eiger Biopharmaceuticals.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Fate Therapeutics (FATE), Mesoblast (MESO), Vericel (VCEL), Surface Oncology (SURF), PDL Biopharma (PDLI), Idera Pharmaceuticals (IDRA), Nightstar Therapeutics (NITE), Adverum Biotechnologies (ADVM), Agenus (AGEN), Jounce Therapeutics (JNCE), NanoString Technologies (NSTG), Cellular Biomedicine Group (CBMG), Allena Pharmaceuticals (ALNA), NantKwest (NK) and Osiris Therapeutics (OSIR).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Pres, CEO, Director & Bus. Founder (Age 54)
- Dr. Jeffrey S. Glenn M.D., Ph.D., Founder, Scientific Advisor & Director (Age 55)
- Dr. Joanne M. J. Quan M.D., Chief Medical Officer (Age 54)
- Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 51)
- Mr. James A. Welch MBA, Chief Financial Officer (Age 60)
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
News headlines about EIGR stock have trended somewhat positive on Thursday, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 48.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Prosight Management LP (5.04%), Sphera Funds Management LTD. (4.51%), BlackRock Inc. (0.77%), Unterberg Capital LLC (0.76%), Eventide Asset Management LLC (0.60%) and Knott David M (0.59%). Company insiders that own Eiger Biopharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn, Joanne Quan and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which major investors are selling Eiger Biopharmaceuticals stock?
Which major investors are buying Eiger Biopharmaceuticals stock?
EIGR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Knott David M, Unterberg Capital LLC, Wedbush Securities Inc., Northern Trust Corp and DRW Securities LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger Biopharmaceuticals.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $12.75.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $144.40 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eiger Biopharmaceuticals (NASDAQ:EIGR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Eiger Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $31.4286, suggesting that the stock has a possible upside of 146.11%. The high price target for EIGR is $39.00 and the low price target for EIGR is $24.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $31.4286 | $29.00 | $29.00 | $33.00 |
| Price Target Upside: | 146.11% upside | 205.26% upside | 81.25% upside | 194.64% upside |
Eiger Biopharmaceuticals (NASDAQ:EIGR) Consensus Price Target History
Eiger Biopharmaceuticals (NASDAQ:EIGR) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Eiger Biopharmaceuticals (NASDAQ:EIGR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 65.92%
Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Joanne Quan | Insider | Sell | 4,000 | $10.00 | $40,000.00 | 4,000 |  |
| 9/1/2017 | Jeffrey S Glenn | Director | Buy | 15,000 | $9.53 | $142,950.00 | 31,355 | |
| 11/18/2016 | Jeffrey S Glenn | Director | Buy | 15,460 | $12.74 | $196,960.40 | 16,355 | |
| 8/18/2016 | James P Shaffer | Insider | Buy | 3,125 | $15.70 | $49,062.50 | 5,620 | |
| 8/18/2016 | Ventures Fund Vi L.P. Vivo | Major Shareholder | Buy | 187,500 | $16.00 | $3,000,000.00 | | |
| 6/22/2016 | James H Welch | CFO | Buy | 2,500 | $19.80 | $49,500.00 | 2,000 | |
| 6/13/2016 | James P Shaffer | Insider | Buy | 1,250 | $22.17 | $27,712.50 | 1,975 | |
| 5/23/2016 | James P Shaffer | Insider | Buy | 1,245 | $19.80 | $24,651.00 | 500 | |
| 4/6/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $18.20 | $872,344.20 | | |
| 4/2/2015 | Rebecque J Laba | VP | Sell | 11,012 | $17.30 | $190,507.60 | | |
| 3/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $24.80 | $1,188,688.80 | | |
| 3/6/2015 | Peter Honig | Director | Sell | 9,700 | $23.74 | $230,278.00 | | |
| 3/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $23.06 | $322,840.00 | | |
| 3/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $18.48 | $143,718.96 | | |
| 2/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $15.86 | $760,185.66 | | |
| 2/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $16.08 | $225,120.00 | | |
| 2/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $16.35 | $127,153.95 | | |
| 1/9/2015 | Jeffrey J Rudy | VP | Sell | 10,000 | $18.51 | $185,100.00 | | |
| 1/7/2015 | Rebecque J Laba | VP | Sell | 20,000 | $17.30 | $346,000.00 | | |
| 1/6/2015 | Krisztina M Zsebo | CEO | Sell | 41,302 | $17.51 | $723,198.02 | | |
| 1/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $19.88 | $154,606.76 | | |
| 12/9/2014 | Jeffrey J Rudy | VP | Sell | 10,000 | $15.00 | $150,000.00 | | |
| 12/9/2014 | Krisztina M Zsebo | CEO | Sell | 41,302 | $15.00 | $619,530.00 | | |
| 12/5/2014 | Rebecque J Laba | VP | Sell | 20,000 | $12.77 | $255,400.00 | | |
| 12/1/2014 | Ryan K Takeya | VP | Sell | 7,777 | $12.01 | $93,401.77 | | |
| 2/4/2014 | Enterprise Partners Management | Major Shareholder | Buy | 133,083 | $8.00 | $1,064,664.00 | | |
| 2/4/2014 | Fredrik Wiklund | VP | Buy | 20,000 | $8.00 | $160,000.00 | | |
| 2/4/2014 | Todd Foley | Director | Buy | 111,608 | $8.00 | $892,864.00 | | |
(Data available from 1/1/2013 forward)
Eiger Biopharmaceuticals (NASDAQ EIGR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
www.reuters.com - May 23 at 5:35 PM |
 | Eiger BioPharmaceuticals: Elucidating The Fundamentals Powering A Big Winner
seekingalpha.com - May 23 at 8:18 AM |
 | Wedbush Comments on Eiger Biopharmaceuticals Inc.'s Q3 2019 Earnings (EIGR)
www.americanbankingnews.com - May 21 at 1:44 AM |
| -$0.83 EPS Expected for Eiger Biopharmaceuticals Inc. (EIGR) This Quarter
www.americanbankingnews.com - May 20 at 9:06 PM |
 | Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 ...
247wallst.com - May 19 at 5:54 PM |
| Eiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 18 at 5:47 PM |
| Eiger Biopharmaceuticals (EIGR) PT Raised to $28.00
www.americanbankingnews.com - May 18 at 5:07 PM |
| Reader Inquiry: Is There Further Upside Ahead For Eiger BioPharmaceuticals?
seekingalpha.com - May 18 at 8:40 AM |
 | Today’s Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics
finance.yahoo.com - May 18 at 8:40 AM |
| Q2 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By Jefferies Group (EIGR)
www.americanbankingnews.com - May 18 at 7:38 AM |
| Eiger Biopharmaceuticals (EIGR) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 17 at 4:17 PM |
| Eiger Biopharmaceuticals (EIGR) Given Outperform Rating at Wedbush
www.americanbankingnews.com - May 17 at 3:27 PM |
| Eiger Biopharmaceuticals (EIGR) Price Target Raised to $39.00 at BTIG Research
www.americanbankingnews.com - May 17 at 2:43 PM |
| Eiger expands license agreement with Merck for Lonafarnib and collaboration with Progeria Research Foundation
seekingalpha.com - May 16 at 5:42 PM |
| Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals
finance.yahoo.com - May 16 at 8:19 AM |
| Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
finance.yahoo.com - May 16 at 8:19 AM |
| B. Riley Analysts Increase Earnings Estimates for Eiger Biopharmaceuticals Inc. (EIGR)
www.americanbankingnews.com - May 16 at 7:16 AM |
| Zacks Investment Research Upgrades Eiger Biopharmaceuticals (EIGR) to Buy
www.americanbankingnews.com - May 15 at 9:18 PM |
| Eiger Biopharmaceuticals (EIGR) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - May 12 at 11:15 AM |
 | UPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19c
www.streetinsider.com - May 11 at 5:58 PM |
| Eiger BioPharma: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 8:27 AM |
| Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:27 AM |
| Q1 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By B. Riley (EIGR)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Eiger BioPharmaceuticals, Inc. (EIGR)
finance.yahoo.com - May 10 at 5:57 PM |
| Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 1:11 PM |
| Eiger Biopharmaceuticals (EIGR) Coverage Initiated at B. Riley
www.americanbankingnews.com - May 9 at 4:59 PM |
| Analysts Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 Earnings Per Share
www.americanbankingnews.com - May 3 at 6:10 PM |
| Eiger Biopharmaceuticals (EIGR) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 1:28 AM |
| Eiger Biopharmaceuticals (EIGR) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - April 26 at 11:19 AM |
| Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%
seekingalpha.com - April 18 at 8:16 AM |
 | Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib ...
www.prnewswire.com - April 17 at 5:54 PM |
| Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
finance.yahoo.com - April 17 at 5:54 PM |
| Zacks: Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 EPS
www.americanbankingnews.com - April 16 at 7:11 AM |
| Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 15 at 8:19 AM |
| Eiger Biopharmaceuticals (EIGR) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM |
| Eiger Biopharmaceuticals (EIGR) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 12 at 5:09 PM |
| Critical Survey: Bavarian Nordic (BVNRY) and Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - April 12 at 3:15 PM |
| Eiger Biopharmaceuticals (EIGR) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - April 10 at 12:01 PM |
| Eiger Biopharmaceuticals Inc. (EIGR) Insider Sells $40,000.00 in Stock
www.americanbankingnews.com - April 4 at 11:37 PM |
| Eiger Biopharmaceuticals (EIGR) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM |
| Eiger BioPharmaceuticals to Participate in Conferences in April
finance.yahoo.com - April 2 at 8:40 AM |
| Eiger Biopharmaceuticals (EIGR) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM |
| Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:30 AM |
| What Should We Expect From Eiger BioPharmaceuticals Inc’s (NASDAQ:EIGR) Earnings In The Next Couple Of Years?
finance.yahoo.com - March 30 at 8:23 AM |
| Eiger Biopharmaceuticals (EIGR) Given "Overweight" Rating at Piper Jaffray
www.americanbankingnews.com - March 28 at 12:58 PM |
| Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
finance.yahoo.com - March 26 at 8:22 AM |
| Wedbush Comments on Eiger Biopharmaceuticals Inc.'s FY2022 Earnings (EIGR)
www.americanbankingnews.com - March 26 at 1:54 AM |
| Eiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
www.streetinsider.com - March 23 at 5:42 PM |
| Eiger Biopharmaceuticals (EIGR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 22 at 9:48 PM |
| Eiger Biopharmaceuticals (EIGR) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - March 22 at 2:26 PM |
Eiger Biopharmaceuticals (NASDAQ:EIGR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eiger Biopharmaceuticals (NASDAQ:EIGR) Income Statement, Balance Sheet and Cash Flow Statement
Eiger Biopharmaceuticals (NASDAQ EIGR) Stock Chart for Thursday, May, 24, 2018
Loading chart…
